vitreomacular traction
Ophthalmology · 2014–2016
2decisions
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ocriplasmin Treatment of vitreomacular traction (VMT), excluding patients with epiretinal membrane (ERM) or adhesion diameter >1500 µm. | Mar 2016 | Recommended with restriction | none received |
| ocriplasmin Treatment of vitreomacular traction (VMT) including those with full-thickness macular hole (FTMH) of diameter ≤400 microns. | Nov 2014 | Not recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.